There were 7 patients (38.9%, one case in chemotherapy group and six cases in immunotherapy group) with HPS and 4/5 screened patients (80%) with positive HAVCR2 gene mutations. The gene discussed is HAVCR2; the disease is Hermansky-Pudlak syndrome.